Androgens and androgen receptors: A clinically neglected sector in breast cancer biology

Journal of Surgical Oncology

Volumn 95, Issue 6, 2007, Pages 437-439

  Moe, Roger E ^a   Anderson, Benjamin O ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; FLUOXYMESTERONE; TAMOXIFEN; TESTOSTERONE;

ADD ON THERAPY; ADRENALECTOMY; BREAST CANCER; BREAST CARCINOMA; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SUBSTITUTION; EDITORIAL; ESTROGEN BLOOD LEVEL; GENETIC PREDISPOSITION; HUMAN; MONOTHERAPY; OVARIECTOMY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ANDROGEN; TAMOXIFEN;

EID: 34248148215     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20722     Document Type: Editorial

References (7)

1. Laughlin G, Barrett-Connor E, Kritz-Silverstein D, et al.: Hysterectomy, Oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo study. J Clin Endocrinol Metab 2000;85:645-651.
2. Lillie E, Bernstein L, Giske U: The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003;5:164-173.
3. Moinfar F, Okeu M, Tsybrovskyy O, et al.: Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 2003;98: 703-711.
4. Agoff S, Swanson P, Linden H, et al.: Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120: 725-731.
5. Doane A, Danso M, Lai P, et al.: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgens. Oncogene 2006;25:3994-4008.
6. Ingle J, Twito D, Schaid D, et al.: Combination hormonal therapy with Tamoxifen plus fluoxymesterone versus Tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991;67:886-891.
7. Morris K, Toth-Fejel S, Schmidt J, et al.: High dehydroepiandrosterone- sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy. Surgery 2001;130:947-953.